Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1811649 | 0.81 | LMNA (0.46) | KMT2AL3MBTL1LMNAKDM4EMEN1 | |
| SCHEMBL8537838 | 0.81 | FBP1 (0.39) | KMT2AL3MBTL1LMNAKDM4EMEN1 | |
| SCHEMBL11848697 | 0.79 | LMNA (0.44) | KMT2AL3MBTL1LMNAKDM4EMEN1 | |
| SCHEMBL8538501 | 0.79 | LMNA (0.44) | KMT2AL3MBTL1LMNAKDM4EMEN1 | |
| SCHEMBL15200988 | 0.77 | LMNA (0.58) | KMT2AL3MBTL1LMNAKDM4EMEN1 | |
| SCHEMBL11731415 | 0.76 | LMNA (0.42) | KMT2AL3MBTL1LMNAKDM4EMEN1 | |
| SCHEMBL1993729 | 0.71 | — | — | |
| SCHEMBL11486200 | 0.71 | MAPT (0.51) | KMT2AL3MBTL1LMNAMEN1TDP1 | |
| SCHEMBL8646262 | 0.69 | MAPT (0.40) | KMT2AL3MBTL1LMNAKDM4EMEN1 | |
| SCHEMBL11450439 | 0.67 | KMT2A (0.58) | KMT2AL3MBTL1LMNAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0043598-B1 | PROCESS FOR THE TRANSFORMATION OF FURFURAL OR 5-NITRO-FURFURAL INTO FURONITRILE OR 5-NITRO-FURONITRILE | AGRIFURANE S.A. (FR) | 1984-07-11 | — | — | EP | claimed |
| US-20250034146-A1 | ELECTRO-PHOTOCHEMICAL SYNTHESIS OF 1,2,4-TRIAZOLO-[4,3-A]PYRAZINE | PURDUE RESEARCH FOUNDATION (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-09-26 | — | — | US | disclosed |
| EP-3860994-B1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2024-08-14 | — | — | EP | disclosed |
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-04-07 | — | — | US | disclosed |
| EP-3860994-A1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | The University of British Columbia (CA) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020069625-A1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-09 | — | — | WO | disclosed |
| US-9617249-B2 | Benzoheterocyclic anti-bacterial agents | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20130143841-A1 | BENZOHETEROCYCLIC ANTI-BACTERIAL AGENTS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2013-06-06 | — | — | US | disclosed |
| US-8362268-B2 | Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110086817-A1 | ANTI-BACTERIAL AGENTS FROM BENZO[D]HETEROCYCLIC SCAFFOLDS FOR PREVENTION AND TREATMENT OF MULTIDRUG RESISTANT BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2011-04-14 | — | — | US | disclosed |
| US-6878705-B2 | 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents | PFIZER (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY | 2004-12-23 | — | — | US | disclosed |
| EP-1465895-A2 | 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003059911-A2 | 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-0043598-B1 | PROCESS FOR THE TRANSFORMATION OF FURFURAL OR 5-NITRO-FURFURAL INTO FURONITRILE OR 5-NITRO-FURONITRILE | AGRIFURANE S.A. (FR) | 1984-07-11 | — | — | EP | disclosed |
| EP-0043598-A1 | Process for the transformation of furfural or 5-nitro-furfural into furonitrile or 5-nitro-furonitrile | AGRIFURANE S.A. (FR) | 1982-01-13 | — | — | EP | disclosed |
| EP-0043598-A1 | Process for the transformation of furfural or 5-nitro-furfural into furonitrile or 5-nitro-furonitrile | AGRIFURANE S.A. (FR) | 1982-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | IL4, ZC3HAV1, IRF3 | KMT2A 731/4885L3MBTL1 3764/4885LMNA 4193/4885 |
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | BRDT, CBFB, CREBBP | KMT2A 428/4885L3MBTL1 533/4885LMNA 227/4885 |
| US-20110086817-A1 | ANTI-BACTERIAL AGENTS FROM BENZO[D]HETEROCYCLIC SCAFFOLDS FOR PREVENTION AND TREATMENT OF MULTIDRUG RESISTANT BACTERIA | SBDS, PYCARD, AAAS | KMT2A 2379/4885L3MBTL1 235/4885LMNA 1073/4885 |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | KMT2A 3139/4885L3MBTL1 2726/4885LMNA 1978/4885 |
| US-20250034146-A1 | ELECTRO-PHOTOCHEMICAL SYNTHESIS OF 1,2,4-TRIAZOLO-[4,3-A]PYRAZINE | CYP4Z1, TYR, PPOX | KMT2A 2735/4885L3MBTL1 4727/4885LMNA 3450/4885 |
| US-20130143841-A1 | BENZOHETEROCYCLIC ANTI-BACTERIAL AGENTS | MRPL21, BCOR, BCR | KMT2A 1565/4885L3MBTL1 143/4885LMNA 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.